Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

about

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

Item

http://www.wikidata.org/entity/Q58567872

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 14 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@en

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@nl

type

Item

label

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@en

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@nl

prefLabel

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@en

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@nl

P1476

Lipids and Atherogenic Indices ...... ong-Term Tocilizumab Treatment

@en

P2093

Angela Rinaldi

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Anelli

http://www.w3.org/2001/XMLSchema#string

P2860

The LDL receptor

Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

P304

2453265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/2453265

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30405318

http://www.w3.org/2001/XMLSchema#string

P921

immunology

atherosclerosis

P932

6204176

http://www.w3.org/2001/XMLSchema#string